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Abstract: The E7 protein of high risk HPV types has been found with different molecular weights, mainly because of 
phosphorylation, an event that changes protein charge and mobility in SDS-PAGE. Distribution of E7 protein in the cellu-
lar compartments has also been subject of debate as some groups report the protein in nucleus and others in cytoplasm. 
The different subcellular distribution and molecular weights reported for the E7 protein suggest the presence of isoforms. 
We examined this possibility by using several antibodies that recognize different epitopes on the HPV-16 E7 protein. We 
showed that E7 is processed in 3 isoforms with different molecular weights and isoelectric points (IEP), and described as 
E7a1 (17.5 kDa, IEP 4.68), E7a (17 kDa, IEP 6.18) and E7b (16 kDa, IEP 6.96). The immunofluorescense results also 
showed that E7 is distributed into different compartments (ER, Golgi and nucleus), which suggest the presence of other 
posttranslational modifications, besides phosphorylation. 
INTRODUCTION 
  Cervical cancer (CC) is one of the most prevalent dis-
eases worldwide. CC is the second major cause of death in 
women from underdeveloped countries [1] and the main 
etiological factor is the human papillomavirus (HPV) persis-
tent infection status. Over 90% of malignant carcinomas of 
the genital tract have HPV DNA sequences; the majority of 
which contain the high risk HPV-16 and 18 types which are 
linked to the progression of cervical lesions and CC [2, 3]. 
  The mechanisms through which HPVs induce cell trans-
formation have been intensively investigated recently. The 
most abundant viral transcripts in tumor and tumor cell lines 
come from the E6 and E7 open reading frames that are 
known to be oncogenic. These two genes from HPV are nec-
essary and sufficient to induce HPV-mediated transformation 
of murine cells [4], immortalize human fibroblasts [5] and in 
cooperation with ras to transform baby rat kidney cells and 
primary human keratinocytes [6, 7]. 
  The transformation capacity of E7 has been shown to be 
limited to the high risk HPV types. The E7 protein is a 98 
amino acid phosphoprotein with a predicted molecular weight 
of 11 kDa, however this protein shows abnormal electropho-
retic mobility in SDS-PAGE gels that generates different mo-
lecular weights from 14 to up to 21 kDa, as reported by differ-
ent groups [8-10]. It has been suggested that the different mo-
lecular weights of E7 and its mobility in SDS-PAGE gels are 
the result of the acidic sequence localized in the amino-
terminal region of the protein, together with its high hydro-
phobicity and high capacity to form oligomers [11-13]. 
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  Studies in high risk HPV types showed that E7 deregu-
lates the cell cycle mainly by binding to and promoting deg-
radation of the tumor suppressor retinoblastoma protein 
(pRb) [14, 15], resulting in the dissociation of pRb from E2F 
transcription factors and the premature cell progression into 
the S-phase of the cell cycle. In a similar way, E7 affects the 
pRb-related pocket proteins p107 and p130 [16, 17]. It has 
also been demonstrated that a phosphorylated E7 isoform is 
able to associate with the histone H1 kinase in the late G2/M 
phase of the cell cycle [16]. Other studies have demonstrated 
that E7 is capable of inducing the enzymatic activity of the 
-glucosidase in the cytoplasm which degrades intracellular 
glucose and provides energy for cell growth and division 
[18]. 
  The different activities of the E7 protein, the heterogene-
ous distribution in different cellular compartments (nucleus 
and cytoplasm) as well as the different molecular weights 
reported suggest the presence of different isoforms of E7. 
We examined this possibility by using polyclonal and mono-
clonal antibodies that recognize different epitopes on the 
HPV-16 E7 protein. We showed that E7 is processed into 3 
forms (E7a1, E7a and E7b), one of which is phosphorylated. 
The molecular weight and the isoelectric point (IEP) as well 
as the cellular localization of the E7 isoforms were different. 
These results demonstrate that there are different isoforms of 
E7 in different cellular compartments and this may be impor-
tant for interaction of the E7 protein with target proteins to 
generate the cellular transformation. 
MATERIALS AND METHODOLOGY 
  Antibodies. The monoclonal antibodies (mAbs) D11, 
B4, C2, A5 and G7 were prepared and characterized in our 
laboratory [19]. Briefly, 20  g of purified recombinant cII-
E7 protein from HPV-16 (expressed and purified from E. 
coli) were used to immunize mice 3 times every two weeks. 
Hybridomas were screened and selected by ELISA against a 16    The Open Virology Journal, 2008, Volume 2  Valdovinos-Torres et al. 
different recombinant E7 protein (MS2-E7) [20]. Further 
characterization was performed by immunoblot, immunopre-
cipitation and immunofluorescence. 
  The anti-E7 (C24 and C89) polyclonal antibodies were 
prepared in our laboratory against the cII-E7 protein purified 
by electro-elution. Briefly, rabbits were immunized 3 times 
with 50  g of recombinant E7 protein and tested for the 
presence of specific E7 antibodies in the same way as mAbs. 
  The anti-E7 (clone ED17, C20), the anti-calnexine (clone 
H-70) and the anti-p21 (C-29) were from Santa Cruz Bio-
technology (Santa Cruz, CA. USA). The anti-GM130 (clone 
35) was from BD Biosciences (San Jose, CA. USA). 
  In Vitro Cell Culture Conditions. CaSki cell line (hu-
man cervical epidermoid carcinoma, naturally HPV-16 trans-
formed), HaCaT cells (normal human keratinocytes) and 
Cos-7 (kidney monkey, SV40 transformed fibroblasts) were 
cultured in Dulbecco's Modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and main-
tained in a humidified atmosphere of 5% CO2/95% air, at 
37°C. 
  In Vivo Cell Labeling. Cells were labeled with 50 
Ci/ml [
35S]-methionine and [
35S]-cysteine (Promix, > 1000 
Ci/mmol, GE Healthcare, Piscataway, NJ. USA), in me-
thionine and cysteine free medium and 5% of dialyzed FBS 
in overnight labeling experiments or with 250 Ci/ml [
35S]-
methionine-cysteine for 15 min in pulse-chase experiments. 
  Cells labeled with [
32P]-orthophosphate were starved in 
0.2% FBS for 48 h and then placed in phosphate free me-
dium for further 2 h, as described previously [21]. After this 
time, cells were incubated with 100 Ci/ml [
32P]-
orthophosphate (3000 Ci/mmol, GE Healthcare, Piscataway, 
NJ. USA) for 1 h (time zero). The remaining cells were in-
cubated with 10% FBS for different times and labeled for 1 h 
with orthophosphate, as above, before cells were collected 
and lysed for immunoprecipitation as described below. 
  Transient Transfection of HPV-16 E7 in Cos-7 Cells. 
Cos-7 cells were transfected using the DEAE-dextran 
method as described previously [22]. Cells were seeded on 8 
well Multitest Slide (MP Biomedical, Solon, OH. USA) and 
grown up to 80% confluence. Cells were transfected with 5 
g of purified pcDNA or pcDNA-E7 plasmid that contains 
the nucleotides 562 to 858 from HPV-16 which encodes for 
the E7 protein (GenBank access AF 477385) (a gift from Dr. 
J. Berumen, Genomic Medicine Laboratory, Hospital Gen-
eral, Mexico D.F.).  Cells were grown for different periods 
of time (0, 2, 4, 8, 16, 24, 48 and 72 h) after which the cells 
were fixed with p-formaldehyde and treated for immunofluo-
rescence, as described below. 
  Immunoprecipitation and SDS-PAGE.  Cells were 
lysed and immunoprecipitated as described elsewhere [23]. 
Briefly, cell monolayers were lysed in radioimmunoprecipi-
tation assay (RIPA) buffer in the presence of protease inhibi-
tors (Complete mini, Roche Diagnostics, Indianapolis, IN. 
USA). Cell lysates were cleared by centrifugation, and su-
pernatants immunoprecipitated for 16 h at 4
oC with 3 g of 
purified IgG anti-E7 mAbs or 30  l of anti-E7 rabbit poly-
clonal antibodies. The antigen-antibody complex was im-
munoprecipitated with Protein A-Sepharose (GE Healthcare,  
 
Piscataway, NJ. USA) for 2 h at 4
oC. Rabbit anti-mouse 
coated Protein A-Sepharose was used for mAbs. The im-
munoprecipitates were dissolved in Laemmli loading buffer 
containing 100 mM dithiothreitol, followed by electrophore-
sis in a 15% SDS-polyacrylamide gel. Gels were treated for 
fluorography with the Enlighting reagent (NEN Life Sci-
ences Products, Boston, MA. USA) and specific bands de-
tected by exposing the gels to X-OMAT film. 
  Immunoblot. Proteins from different cell lines were ex-
tracted in RIPA buffer, as described previously [24], in the 
presence of protease inhibitors (Roche Diagnostics, Indian-
apolis, IN. USA). Total protein extracts (1 mg/ml) were in-
cubated with the C24 polyclonal antibody and processed for 
immunoprecipitation as mentioned before. Immunoprecipi-
tates were separated on 15% SDS-PAGE gels and transferred 
to nitrocellulose Protean membranes (0.45 m, Whatman 
International Ltd., Middlesex, UK), as described by Towbin 
and coworkers [25]. The membranes were blocked with 
PBS-0.5% Tween containing 10% skim milk for 30 min at 
room temperature. Subsequently, the membranes were incu-
bated with a 1:200 dilution of anti-E7 polyclonal antibodies 
or with a 1:100 dilution of anti-E7 mAbs in PBS-0.5% 
Tween and 5% skim milk, overnight. Blots were washed 
with PBS-0.5% Tween followed by incubation for 1 h under 
the same conditions with the secondary goat anti-rabbit or 
rabbit anti-mouse IgG antibodies conjugated with horserad-
ish peroxidase (DAKO, Carpinteria, CA. USA). The mem-
branes were developed according with the chemilumines-
cence kit of Perkin Elmer (Waltham, Massachusetts, USA) 
manufacturer instructions. Membranes were exposed to X-
OMAT film. 
 Indirect  Immunofluorescence. Cells at 80% confluence 
were rinsed with PBS and fixed with 4% p-formaldehyde in 
PBS at room temperature for 20 min followed by treatment 
with permeabilization buffer [1% BSA in PBS containing 
either 3% Triton X-100 (for nuclear structures) or 0.2% 
saponine (for cytosolic and internal membranes)] for 20 min 
at 4
oC. Subsequently, cells were incubated with anti-E7 anti-
bodies (serum diluted 1:100 for anti-E7 polyclonal Abs and 
2 ng/ l of purified IgG for anti-E7 mAbs in permeabilization 
buffer) for 16 h at 4
oC. Slides were rinsed with PBS and in-
cubated for 2 h at 4
oC with anti-rabbit IgG conjugated with 
Alexa 488 (green) or anti-mouse IgG conjugated with Alexa 
594 (red) (dilution 1:250 and 1:800, respectively, Molecular 
Probes, Carlsbad, CA. USA). Specimens were mounted in 
50% glycerol in PBS and visualized under the Confocal Mi-
croscope 510 META (Carl Zeiss, Massachusetts, USA) un-
der the Plan-Neofluor 100X /1.3 oil Ph3 lent. 
  2-dimensional Polyacrylamide Gel Electrophoresis 
(2D Gels). Immunoprecipitated E7 protein was treated for 
isoelectrofocusing (IEF), as described previously [26] with 
some modifications. Briefly, E7 immunoprecipitates were 
dissolved in IEF sample buffer (9.5 M urea, 2% NP40, 2% 
ampholines 3-10, 100 mM DTT). IEF used 7% ampholines 
(GE Healthcare, NJ. USA) pH 3-9 in 2.5 mm diameter poly-
acrylimide gel tubes and fixed to the adaptor for slap gels 
electrophoresis apparatus (BRL Wrightsville, PA. USA). 
The IEF was carried for 16 h at 400 V and electrophoresis 
for the second dimension was run as described before. The 
gels were treated for fluorography as described previously. 
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RESULTS 
  Characterization of HPV-16 E7 Protein with Differ-
ent Antibodies. It has been reported that E7 protein shows 
different molecular weights and that the phosphorylation 
process is probably one of the causes for these differences. 
Thus, we decided to identify the different forms reported 
using polyclonal and monoclonal antibodies, produced in our 
laboratory that can differentiate the various isoforms. To this 
end, CaSki cells were labeled with [
35S]-methionine-cysteine 
for 16 h and the E7 protein immunoprecipitated with the 
different antibodies as described in Materials and Methodol-
ogy. The result in Fig. (1) shows an E7 protein of 16 kDa 
that was immunoprecipitated with the polyclonal antibodies 
C24 and C89, as well as with the mAbs G7, B4 and the 
commercial ED17. However, a 17 kDa E7 protein was ob-
served only with the polyclonal antibodies (C24 and C89) 
(Fig.  1A). In contrast, none of these two bands were ob-
served in immunoprecipitates from HaCaT cells that were 
used as negative controls (Fig. 1A), or with control rabbit or 
mouse serum (data not shown). 
 
Fig. (1). Recognition of HPV-16 E7 protein by monoclonal and 
polyclonal antibodies. (A) HaCaT (H) and CaSki (C) cells were 
labeled with [
35S]-methionine-cysteine and immunoprecipitated 
with different anti-E7 polyclonal (C24, C89) and mAbs (G7, B4, 
C2, D11, C20, A5, ED17). The arrows show a 16 kDa band recog-
nized by all antibodies, and a 17 kDa band detected only by poly-
clonal antibodies. (B) Cell extracts were first immunoprecipitated 
with the C24 polyclonal antibody, samples treated for Western blot 
and tested with polyclonal and mAbs. The arrow shows the E7 
protein of 16 kDa. 
  We also tested the capacity of the antibodies to recognize 
the E7 protein by Western blot as the different molecular 
weights of the E7 protein could be the result of the different 
techniques used. Previously, we have shown that the sensi-
tivity of the direct Western blot for E7 is low [27] and there-
fore, it is necessary to carry out an immunoprecipitation–
Western blot to visualize the E7 protein from cell extracts. In 
this way, cells were immunoprecipitated first with the poly-
clonal C24 antibody as this antibody recognized 2 forms of 
E7 protein. The precipitates were separated on a SDS-PAGE 
gel, transferred to Protean membranes and tested with the 
different mAbs as described previously. The results in Fig. 
(1B) showed that 5 of the 6 mAbs tested recognized the 16 
kDa band of the E7 protein. This band was also recognized 
by the commercial mAb ED17 acquired from Santa Cruz, 
which was used as a positive control. The recognition of 16 
kDa band is specific, as this was not present when the mAbs 
were tested with the HaCaT immunoprecipitates used as 
negative controls (Fig. 1B). In the case of the polyclonal 
antibodies (C24 and C89), they only recognized the 16 kDa 
band but not the 17 kDa band in the Western blot. It is possi-
ble that these antibodies only recognize a conformational 
epitope in the E7 protein that is lost by denaturation during 
the Western blot process (Fig. 1B). 
  Processing of HPV-16 E7 Protein. Processing of E7 
protein was determined by pulse-chase labeling of CaSki 
cells and immunoprecipitated with C89 polyclonal antibody 
(Fig. 2). The top panel of Fig. (2) shows the electrophoretic 
analysis of immunoprecipitates of [
35S] methionine-cysteine 
labeled E7 protein after 15 min pulse, followed by chase of 
up to 6 h. It is clear that the E7 protein was synthesized after 
the 15 min pulse as a 17 kDa protein (E7a) that remained 
stable for up to 1 h and subsequently disappeared (Fig. 2). 
After 1 h of chase the E7a protein was processed to a 16 kDa 
band (E7b) and was stable for up to 3 h of chase (Fig. 2). 
This pattern of bands was not observed in the immunopre-
cipitates of labeled HaCaT cells used as control (Fig. 2). The 
15 kDa band observed in HaCaT cells at 6 h (smaller than 
the one observed for E7 in CaSki cells) is a non-specific 
band as it is not consistently observed in experiment repeti-
tions. The bands of the fluorography were scanned to calcu-
late the half-life of the E7 proteins according to Belle and 
coworkers [28]. The results showed that the half-life of the 
E7a protein was only 50 min and 70 min for the faster mov-
ing band of E7b (Fig. 2, lower panel). The presence of a non-
specific 21 kDa band in pulse-chase cells (HaCaT and 
CaSki) was due to the high levels of label used in this kind 
of experiments. 
  Recognition of 3 Different forms of HPV-16 E7 Pro-
tein by Differences in Charge.  The pulse-chase experi-
ments showed that the E7a protein was processed to a faster 
moving form described as E7b. At this point, it was not clear 
if there was an actual chemical modification of the protein, 
or if the differences were only due to a conformational 
change. For this reason, it was important to determine if 
there was any difference in charge in addition to the differ-
ence in molecular weight between these 2 isoforms of E7. 
Isoelectrofocusing of immunoprecipitates (C89 antibody) of 
overnight [
35S] methionine-cysteine labeled E7 proteins was 
performed followed by SDS-PAGE gels. The separation of 
the E7 proteins in a pH gradient showed that E7a and E7b 
have different net charge (Fig. 3, CaSki, spots 2 and 3 re-
spectively). However, unexpectedly an additional form of   
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Fig. (2). Processing and half-life of the HPV-16 E7 protein.  
HaCaT and CaSki cells were pulse labeled with [
35S]-methionine-
cysteine for 15 min and chased for different times (0, 1, 3 and 6 h). 
Upper panel: Cell extracts were immunoprecipitated with the anti-
E7 polyclonal C89 antibody, samples separated by SDS-PAGE gel 
and bands visualized by auto-radiography. The arrows showed a 17 
kDa (E7a) and a 16 kDa (E7b) bands. The 15 kDa band observed in 
HaCaT cells is a non-specific band as it is not consistently observed 
in experiment repetitions. Lower panel: Bands were scanned and 
plotted in a graph to calculate the half-life of the different forms of 
E7 protein. 
the E7 protein in the extract of CaSki cells that was not re-
solved in one dimension gels was found. The third band ob-
served (E7a1) showed a molecular weight of 17.5 kDa (Fig. 
3, CaSki, spot 1). The IEP for each form of E7 protein was 
calculated as 4.68 for E7a1 (spot 1), 6.18 for the E7a form 
(spot 2) and 6.96 for E7b (spot 3). This difference in charge 
among the 3 isoforms of E7 protein, suggests that the pro-
teins are modified in some ways in two different steps. 
 
Fig. (3). Characterization of the HPV-16 E7 proteins by IEP. 
HaCaT and CaSki cells were labeled with [
35S]-methionine-cysteine 
and immunoprecipitated with the C89 polyclonal antibody. The 
immunoprecipitates were separated in the first dimension in a pH 
gradient from 3-9 for 16 h. The second dimension was run in a 15% 
PAGE gel and treated for fluorography. The numbers over the 
CaSki panel show the localization of the 3 isoforms of HPV-16 E7 
proteins (E7a1, E7a and E7b) and these spots were not observed in 
the HaCaT control cells. 
  Phosphorylation of the HPV-16 E7 Protein.  Previ-
ously, it has been reported that posttranslation phosphoryla-
tion occurs in E7 [29]. Accordingly, we decided to identify 
which of the E7 forms was phosphorylated. To this end, cells 
were starved for 48 h and subsequently labeled with [
32P]-
orthophosphate for 1 h at different times after protein syn-
thesis reactivation by addition of FBS as described in Mate-
rials and Methodology, and separated in 15% SDS-PAGE 
gel. The starvation step in this system was introduced to 
avoid incorporation of [
32P]-orthophosphate in the peptide 
backbone and to look for novel protein phosphorylation. The 
result showed a phosphorylated E7 protein with an apparent 
molecular weight of 17.5 kDa (E7a1) that accumulates over 
the time, however, the 16 kDa protein band (E7b) was not 
observed at any time, suggesting that this E7 isoform is not 
phosphorylated (Fig. 4). Several reports have shown that E7 
can be phosphorylated in at least 2 different sites [21, 30, 
31], and this could explain the presence of a broad band that 
could contain the 17.5 kDa (E7a1) and the 17 kDa (E7a) 
proteins that were observed in the 2D gels. 
 
Fig. (4). Phosphorylation of HPV-16 E7 protein. CaSki cells 
were starved for 16 h, labeled with [
32P]-ortophosphate and har-
vested at different periods of time. Cell extracts were immunopre-
cipitated with the anti-E7 polyclonal C89 antibody or with control 
rabbit serum. The precipitates were separated in a 15% acrylamide 
gel and visualized by autoradiography. The arrow shows the phos-
phorylated E7 protein of 17.5 kDa. 
  Cellular localization of the different forms of HPV-16 
E7 proteins. Up to this point, the results showed that HPV-
16 E7 from CaSki cells is processed in 3 different molecular 
weight forms, one of which is phosphorylated (E7a1). We 
also demonstrated that polyclonal and mAbs recognized dif-
ferent forms of the E7 protein. Taken together, this informa-
tion made us wonder about the cellular localization of the 3 
isoforms of E7. Thus, we used the different polyclonal and 
mAbs in cells fixed for immunofluorescence and co-
localized the E7 protein with antibodies against cellular 
markers for nucleus (p21), endoplasmic reticulum (ER; 
calnexin) and Golgi (GM130), as previously reported [32-
34]. The results in Fig. (5) showed that the polyclonal anti-
body C89 recognized the E7 protein in the nucleus as wells 
as in cytoplasm, while the C24 polyclonal mainly stained the 
cytoplasm. When mAbs were tested together with the cellu-
lar markers it was evident that the ED17 antibody recognized 
the E7 protein in the nuclear compartment as this antibody 
co-localized only with the p21 nuclear marker (Fig. 5, ED17, 
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merged). The E7 protein recognized by the B4 mAb co-
localized only with the calnexin marker, which suggests that 
the E7 form recognized by this antibody is present in the ER 
(Fig.  5, B4, merged). However, when the D11 mAb was 
tested a small part of this antibody co-localized with the 
calnexin marker of ER and a stronger co-localization signal 
was observed with the Golgi GM130 marker (Fig. 5, D11, 
merged). These results demonstrated that the E7 protein is 
recognized in different cellular compartments by different 
antibodies. 
 In  Vivo Cellular Processing of HPV-16 E7 Protein in 
Transfected Cells. The presence of different forms of E7 
localized in different cellular compartments prompted us to 
analyze the processing of the E7 protein in the cell. To ana-
lyze the E7 processing, Cos-7 cells were transiently trans-
 
Fig. (5). Subcellular localization of HPV-16 E7 proteins by immunofluorescence. Cells were fixed with p-formaldehyde and permeabi-
lized with 0.2% saponine. Cells were tested with the different anti-E7 polyclonal (C89 and C24) and mAbs (ED17, B4, D11). Biological cell 
markers were used to identify ER (calnexin), Golgi (GM130) and nucleus (p21) and co-localized with the immunological detected E7 pro-
tein. Secondary fluorescent antibodies were anti-rabbit IgG conjugated with Alexa 488 (green) or anti-mouse IgG conjugated with Alexa 594 
(red). The merged image is shown in the right side of the figure and positive co-localization is observed in yellow color. Images were taken 
at a magnification of 1000X using Confocal microscope. 
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fected with the pcDNA-E7 plasmid to investigate de novo 
expression and localization of E7 protein at different periods 
of time and tested for immunofluorescence, as described in 
Materials and Methodology. The results in Fig. (6) show that 
the polyclonal C89 antibody identified 3 different patterns of 
E7 staining; at first E7 is recognized by 16 h after transfec-
tion in the cytoplasm of the cells. By 24 h the E7 protein 
became concentrated in the periphery of the nucleus and by 
48 h the fluorescence was only observed into the nucleus and 
concentrated in the nucleolus (Fig. 6, C89). With the D11 
antibody (identifies E7 in ER and Golgi) a very light cyto-
plasmic fluorescence signal was observed by 16 h after E7 
transfection, that became very strong by 24 h (Fig. 6, D11). 
However, the fluorescence signal disappeared totally by 48 h 
after Cos-7 cells transfection. In contrast, the B4 mAb that 
recognized only the E7 protein in the ER showed a strong 
fluorescence signal only at 24 h after E7 transfection (Fig. 6, 
B4). While the ED17 mAb that recognized E7 protein only 
in the nucleus identified the protein only after 24 h and the 
fluorescence signal was still present by 48 h (Fig. 6, ED17). 
In these experiments the presence of E7 expression was not 
detected, with any of the different antibodies tested, before 
the 16 h and after 48 h (data not shown). The specificity of 
each one of the antibodies was determined by immunofluo-
rescence using Cos-7 transfected cells with pcDNA plasmid 
alone as it was done for the pcDNA-E7 plasmid (data not 
shown). In Fig. (6), only the 24 h time pcDNA control is 
shown for each one of the antibodies as this was the time of 
the highest E7 expression in the transfected cells. 
DISCUSSION 
  The E7 protein is a very well studied protein that had 
been demonstrated to interact with a variety of target pro-
teins such as the pocket proteins (pRb, p130 and p107) [14, 
15], proteins involved in cell cycle (E2F-Cyclin A complex, 
Cyclin E, p21
Waf1, p27
Kip1) [35-39], transcription factors 
 
Fig. (6). Processing of the HPV-16 E7 protein under in vivo conditions. Cos-7 cells were transiently transfected with the pcDNA-E7 
plasmid and chase for different periods of time (8, 16, 24 and 48 h). Harvested cells were fixed with 4% p-formaldehyde, permeabilized as 
described in Material and Methodology and tested with different anti-E7 antibodies. The antibodies tested were C89 polyclonal antibody, and 
D11, B4 and ED17 mAbs.  Secondary fluorescent antibodies were anti-rabbit IgG conjugated with Alexa 488 (green) or anti-mouse IgG 
conjugated with Alexa 594 (red). Cos-7 cells transfected with pcDNA plasmid alone at 24 h was used as control of the system as this was the 
time for the highest expression of the E7 protein observed. Images were taken at a magnification of 1000X using Confocal microscope. 
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(pCAF acetyltransferase, TBP, AP-1 family factors) [40-43] 
and with the senescence-regulating protein DEK [44], among 
others. All of these target proteins are present in the nucleus; 
however the reports about the distribution of the E7 in the 
cell have shown that this protein is present not only in nu-
cleus but also in the cytoplasm. We believe that this differen-
tial distribution of E7 in the cells is due to the presence of 
different isoforms of E7 that are produced during its cellular 
processing. To test this hypothesis, monoclonal and poly-
clonal antibodies that recognize different epitopes in the E7 
protein were developed in our laboratory. The results 
showed the presence of 3 isoforms of HPV-16 E7 protein 
that vary in molecular weight and IEP. These E7 proteins 
were described as E7a1 (17.5 kDa and IEP of 4.68), E7a (17 
kDa and IEP of 6.18) and E7b (16 kDa and IEP of 6.96). The 
half-lives of the E7 proteins were calculated as 50 min for 
E7a and 70 min for E7b. These results are consistent with a 
previous report that showed that the half-life of E7 from 
CaSki cells was 55 min and 70 min in SiHa cells, although 
these researchers only identified one E7 band protein in each 
cell line [30]. The difference between Smotkin and Wettstein 
results and ours was the use of different anti-E7 antibodies 
and that these recognized the different isoforms of the E7 
protein. 
  In the pulse-chase experiments we identified that E7 is 
initially synthesized as a 17 kDa protein and after approxi-
mately 1 h, it is processed to a faster moving band of 16 kDa 
with a short half-life. These results suggest that E7 under-
goes some posttranslational modifications that generate the 
shift in molecular weight. A known modification for E7 is 
the phosphorylation of the serine residues 31 and 32 [29, 45], 
although serine 71 is also a potential phosphorylation site 
[31, 46]. Our results showed a broad phosphorylated band of 
a calculated molecular weight of 17.5 kDa that could be the 
17 kDa band that was recognized in the immunoprecipita-
tions. The difference in molecular weight could be due to the 
change in charge that makes the protein to be retarded in the 
SDS-PAGE gel. Another possibility is that the antibodies did 
not recognize efficiently the non-phosphorylated protein as 
has been reported for other mAbs [47], suggesting that the 
phosphorylated E7 protein has distinct antigenic properties 
(conformational changes). However, these results did not 
account for the lower molecular weight band of 16 kDa 
(E7b) that was identified in the Western blot and in the im-
munoprecipitations. Another as yet unidentified modification 
could exist and be the reason for the presence of this faster 
moving E7b protein. 
  According to the HPV-16 E7 protein sequence the calcu-
lated IEP of this protein is 4.05, however, when this charac-
teristic was measured with recombinant E7 protein produced 
in bacteria the IEP obtained was 5.4 [48]. When the IEP of 
the HPV-18 E7 protein produced in vitro (using rabbit re-
ticulocyte lysates) or immunoprecipitated from HeLa cells, 
there were 3 bands of the same molecular weight, but differ-
ent IEP [49]. The researchers suggested that this was a typi-
cal pattern for phosphorylated proteins and this was similar 
to what we found. However, in our experiments not only the 
IEP, but also the molecular weights of the E7 proteins (E7a1, 
E7a and E7b), were different in the 2D gels. This again sug-
gests that the C89 polyclonal antibody is recognizing differ-
ent epitopes of the E7 isoforms that have not been fully 
characterized. 
  At least 2 distinct molecular weights have been reported 
for HPV-16 E7 by 2 different groups [50, 51]. However, the 
C89 antibody was able to recognize simultaneously 2 forms 
of E7 by radio-immunoprecipitation and 3 when 2D gels 
were used. It has been shown that E7 is highly hydrophobic 
and that this characteristic together with its conformational 
structure produce an anomalous electrophoretic behavior. 
Purified E7 protein is present as oligomers, and tends to be 
soluble and with a molecular weight close to the calculated 
in the presence of 8M urea [13, 52]. It is possible that we 
were able to visualize the 3 forms of E7 in the 2D gels, not 
only because the difference in charge, but because the pro-
teins were solubilized in 8M urea. 
  When we examined the localization of the different E7 
forms in the cellular compartments by immunofluorescence 
staining, it was observed that the E7 protein was first ob-
served in the ER as this was the first signal observed with the 
antibodies (16 h). Subsequently, the E7 protein was visual-
ized in the Golgi compartment (16 to 24 h) and finally trans-
located to the nucleus (48 h), where it probably interacts 
with target proteins, such as pRb. From this work, it is clear 
that the E7b (16 KDa, recognized by mAbs) isoform is local-
ized in the cytoplasm and nucleus, but the localization of the 
17 and 17.5 kDa E7 isoforms still needs to be determined as 
there are not specific antibodies available to differentiate 
them. According with this processing of the E7 protein, it is 
possible that the protein encounters some posttranslational 
modifications during the transit through different cellular 
compartments that allow the final localization of the protein. 
Studying the amino acid sequence of the HPV-16 E7 protein, 
it could be observed that it contains a consensus sequence for 
glycosylation of Asp 29, has 2 sulfation sites (Tyr 23 and 26) 
and 5 phosphorylation sites besides the already known Ser 
31, 32 and 71 [46]. Up today, only phosphorylation has been 
reported for the E7 protein and this posttranslational modifi-
cation only accounts for the difference in charge identified in 
the 3 different forms of E7, but other modifications will still 
need to be studied to clarify the differences on molecular 
weight identified by our polyclonal and mAbs. 
  During the processing of the E7 protein in the Cos-7 
transfected cells, the protein is localized at the perinuclear 
zone by 24 h after being synthesized. This localization is in 
agreement with a previous report that showed that E7 from 
HPV-16 was observed in ER, cytoplasm and the nuclear 
membrane, where E7 was able to activate the -glucosidase 
enzyme in an allosteric way [18]. Subsequently, during the 
expression of the E7 protein in the Cos-7 transfected cells 
(48 h), the protein was visualized in the nucleus and relocal-
ized into the nucleolus of the cells. These structures have 
also been reported to be present in CaSki cells, but only dur-
ing the G2/M cell cycle phase [53]. The nuclear localization 
of the E7 protein has been reported in several studies [50, 51, 
53, 54]; however, this protein does not contain a consensus 
sequence to be translocated into the nucleus. The transloca-
tion of the E7 protein into this compartment has been re-
ported to be through a non-conventional Ran-GTP pathway 
and an intermediary carrier protein seems to be involved 
[54]. Alternatively, in vitro characterization of E7 protein 
has demonstrated that formation of dimers and tetramers of 
E7 depends on pH changes which allow exposure of hydro-
phobic epitopes [13]. It is also well established that cell 
compartments are microenvironments that functions at dif-22    The Open Virology Journal, 2008, Volume 2  Valdovinos-Torres et al. 
ferent pHs [55, 56]. It is possible then, that final localization 
of the different isoforms of E7 in the cell could be drived by 
exposure of different epitopes due to oligomerization of E7 
induced by changes in pH, during their transit through the 
different cellular compartments. 
  The low levels of E7 expression of the high risk HPVs, 
together with the short half-life of this protein, makes it dif-
ficult to carry on with biochemical experiments helpful to 
completely characterize this protein. Most of the information 
obtained in an effort to biochemically characterize E7 pro-
tein has been generated from recombinant E7 protein pro-
duced in bacteria or produced under in vitro conditions. 
However, some of the posttranslational modifications of the 
proteins are predominantly observed in eukaryotic cells. The 
lack of these modifications would change the molecular 
weights as well as the net charges of the protein, making it 
difficult to detect the intermediates or processed forms of the 
HPV-16 E7 protein that are reported in this paper as we used 
eukaryotic cell cultures. In this way, 3 forms of HPV-16 E7 
proteins were identified with polyclonal and mAbs that 
showed different molecular weights and different IEPs 
(E7a1, E7a and E7b). Due to the fact that the different anti-
bodies recognized different epitopes, the E7 protein was rec-
ognized in different cellular compartments at different times 
during its processing. 
  The E7 protein has been recognized as a multifunctional 
protein that interacts with a high variety of target proteins. It 
will be of great interest to identify the complete molecular 
processing of the E7 protein (other posttranslational modifi-
cations) that will allow a better knowledge about the struc-
ture and the biological activity of this oncogenic protein and 
its role in the transformation process. 
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